RE:RE:Observations & QuestionsMacer ... Thanks for the input. That's very appreciated.
What I observed at the meeting yesterday and from the videos is that the clinical team is on the same page as the team at TLT. _______________
Macer - (6/28/2019 2:29:24 PM) RE:Observations & Questions
Questions were asked about the patients in phase 1.
They will continue to be followed by their uro oncologists at PMH.
TLT is not priviledged to track their personal health data ouside of the study but if they hear about their longterm follow up and have consent they will share it.
They did not comment on the costs of the drug but did mention that they have enough of it to finish phase 2. They also continue stability testing and Shawn expects that the shelf life will be fine up until 5 years (best guess). The fiberoptic and drug delivery components are disposables and likely are not outrageously expensive. Clinic use would be very beneficial as it will drive costs down and increase sales of the 3200. Kipton also had some interesting ideas on recurring revenue with the TLT 2000 following most recent upgrades (planning to build that back up again).
NIMBC is the main focus right now, and should be until the trial is up and running in at least 5-10 North American sites. Arkady mentioned that pre-clinical work continues in other indications and looks promising but they have to get NIMBC going as a priority before spreading to thin. I agree. Once we start getting an indication that the patients in phase 2 are starting to look a lot like patients #5 and 6 we are off to the races.
Look for more clinical sites to come on board over the summer across Canada and hopefully FDA submission in the next few weeks. They will also announce first patient treated at PMH.
What I observed at the meeting yesterday and from the videos is that the clinical team is on the same page as the team at TLT. This is not always the case with sponsored relationships like this. I have seen drug companies blow deals because they want to control how physician prescribe and utlize their products only to end in failed clinical trials. Looking for good things from this company, its taking a while but we will definetly get there.
Macer